Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Advanced Systemic Mastocytosis
NCT02415608Phase 2Terminated
- Start
- Mar 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in systemic mastocytosis (SM). Started Mar 2015; status: terminated.
02
Drugs
ibrutinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT02415608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415608.